Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

With APLLTD's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.69500
forwardPE 21.22189
debtToEquity 24.23200
earningsGrowth -0.12000
revenueGrowth 0.16700
grossMargins 0.71811
operatingMargins 0.11475
trailingEps 29.71000
forwardEps 43.50000

APLLTD's current ratio of 1.695, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as APLLTD has enough cash and current assets to handle its immediate liabilities comfortably.
APLLTD's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
APLLTD's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making APLLTD a financially resilient company with lower exposure to debt-related pressures.
APLLTD's low earnings and revenue growth suggest shrinking profits. This negative trend could indicate that the company is struggling to maintain its financial performance and may face challenges ahead.
With negative gross and operating margins, APLLTD is facing losses at both the production and operational levels. This signals significant financial strain and may indicate that the company is struggling to manage costs effectively.
APLLTD's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in APLLTD's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

The price of Alembic Pharmaceuticals Limited has repeatedly been close to the lower limit of price projections. This trend suggests that the stock may be underperforming, raising concerns among investors about future performance.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


APLLTD stock was bought in 11 transactions, while the market price was at 835.5045443448154.During the period under consideration, there were no buy transactions.APLLTD's current price levels are experiencing more selling activity, which could signal bearish sentiment. If this trend continues, it may lead to further price declines, as increased selling pressure typically indicates investor concerns about the stock's future performance.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


The recent buy bias from analysts suggests APLLTD is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, APLLTD appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.